Ancillary and Molecular
Testing Pathways
Caris MI Tumor Seek Hybrid™
Caris Assure™ Therapy Selection
Prolaris® Prostate Tumor Test
knowerror® system
UroSeq
The UroSeq test is a molecular diagnostic test designed to detect genetic mutations and alterations in urine samples, helping identify and monitor bladder cancer. It is particularly useful for patients with a history of bladder cancer, offering a non-invasive method for ongoing surveillance and aiding in early detection of recurrence.
Decipher® Prostate Test
MyRisk® Germline Test
The MyRisk® Germline Test is a genetic screening that detects inherited mutations associated with an elevated risk for multiple cancers, including breast, ovarian, and colorectal. It’s especially useful for individuals with a personal or family history of cancer, helping guide proactive screening and prevention measures.
Artera AI® Prostate Test
The ArteraAI Prostate Test is an artificial intelligence biomarker test that analyzes digital images from prostate biopsies alongside clinical data. It predicts the potential benefits of hormone therapy and estimates long-term outcomes for patients diagnosed with localized prostate cancer who have not previously received hormone therapy. This test helps identify those who may benefit from intensified treatment. With PathNet, results are available in 1-2 days without requiring new tissue samples.
